GT200600155A - Compuestos utiles en terapia - Google Patents

Compuestos utiles en terapia

Info

Publication number
GT200600155A
GT200600155A GT200600155A GT200600155A GT200600155A GT 200600155 A GT200600155 A GT 200600155A GT 200600155 A GT200600155 A GT 200600155A GT 200600155 A GT200600155 A GT 200600155A GT 200600155 A GT200600155 A GT 200600155A
Authority
GT
Guatemala
Prior art keywords
therapy
useful compounds
compounds
useful
menorragy
Prior art date
Application number
GT200600155A
Other languages
English (en)
Inventor
Paul Anthony Bradley
Kevin Neil Dack
Ian Roger Marsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600155A publication Critical patent/GT200600155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA GENERAL I EN LA QUE R1,R2,R8,R9,R10, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE PROGESTERONA POR LO QUE SON DE UTILIDAD EN CUADROS DE ENDOMETRIOSIS, FIBROIDES UTERINOS, MENORRAGIA, ADENOMIOSIS, DISMENORREA.
GT200600155A 2005-04-20 2006-04-19 Compuestos utiles en terapia GT200600155A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67354405P 2005-04-20 2005-04-20

Publications (1)

Publication Number Publication Date
GT200600155A true GT200600155A (es) 2007-04-18

Family

ID=35044974

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600155A GT200600155A (es) 2005-04-20 2006-04-19 Compuestos utiles en terapia

Country Status (12)

Country Link
US (2) US7482375B2 (es)
EP (1) EP1874732A1 (es)
JP (1) JP2008536910A (es)
AR (1) AR053587A1 (es)
CA (1) CA2604218A1 (es)
DO (1) DOP2006000088A (es)
GT (1) GT200600155A (es)
NL (1) NL1031626C2 (es)
PE (1) PE20061316A1 (es)
TW (1) TW200716609A (es)
UY (1) UY29486A1 (es)
WO (1) WO2006111856A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
US20080096950A1 (en) * 2006-10-19 2008-04-24 Karl Richard Gibson Compounds Useful In Therapy
PE20081803A1 (es) * 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
WO2008135824A1 (en) * 2007-05-02 2008-11-13 Pfizer Limited Oxyalkylpyrazole compounds useful in therapy
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
WO2009119880A1 (en) * 2008-03-26 2009-10-01 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA2735931A1 (en) * 2008-09-18 2010-03-25 Pfizer Limited Amide compounds useful in therapy
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
BR112014029131B1 (pt) 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
WO2015171392A1 (en) * 2014-05-06 2015-11-12 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
US10786461B2 (en) 2014-11-17 2020-09-29 Context Biopharma Inc. Onapristone extended-release compositions and methods
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621024C2 (de) * 1986-06-20 1999-10-28 Schering Ag 11beta-Phenylestradiene, deren Herstellung und diese enthaltende pharmazeutische Präparate
NZ529403A (en) 2001-04-10 2005-06-24 Pfizer Pyrazole derivatives for treating HIV
US6933312B2 (en) * 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives

Also Published As

Publication number Publication date
US7482375B2 (en) 2009-01-27
UY29486A1 (es) 2006-11-30
EP1874732A1 (en) 2008-01-09
US20090099209A1 (en) 2009-04-16
JP2008536910A (ja) 2008-09-11
NL1031626A1 (nl) 2006-10-23
AR053587A1 (es) 2007-05-09
DOP2006000088A (es) 2006-10-31
WO2006111856A1 (en) 2006-10-26
CA2604218A1 (en) 2006-10-26
NL1031626C2 (nl) 2007-03-19
PE20061316A1 (es) 2007-01-13
TW200716609A (en) 2007-05-01
US20060241125A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
GT200600155A (es) Compuestos utiles en terapia
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
GT200500101A (es) Compuestos de metil-aril o heteroaril-amida sustituida
GT200600184A (es) Derivados de purina
GT200500226A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
GT200600107A (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
GT200400013A (es) Compuestos de pirazolotriazina y usos de los mismos
GT200300014A (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
SV2009003276A (es) Antagonistas de receptor de orexina de diazepan sustituido
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
ECSP11011189A (es) Moduladores de los receptores tipo toll
GT200600024A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
GT200600422A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
GT200300028A (es) Derivados iii de dihidrobenzodiacepina-2-ona
CR8566A (es) 2,3,4,5-Tetrahidro-1H-Benzo [d] Azepinas 6-Substituidas como agonistas del receptor 5-HT2c
GT200600255A (es) Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a
GT200600246A (es) Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada
MX2010008375A (es) Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
UY32996A (es) Antagonistas del receptor crth2 basados en indol
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
PE20081409A1 (es) Antagonistas del receptor de progesterona